Ftse Mib
34.374,77
0,55%
DAX
20.024,66
0,58%
S&P 500
5.868,55
-0,22%
NASDAQ
19.280,79
-0,16%
Bitcoin
96.878,52
-0,02%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Kiromic BioPharma Inc (KRBP) Kiromic BioPharma Inc (KRBP) Notizie

KRBP

Kiromic BioPharma (KRBP)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KRBP
DataOraFonteTitoloSimboloCompagnia
19/09/202422:30Business WireKiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialNASDAQ:KRBPKiromic BioPharma Inc
19/09/202414:00Business WireKiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous RecommendationNASDAQ:KRBPKiromic BioPharma Inc
21/08/202422:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRBPKiromic BioPharma Inc
14/08/202414:00Business WireKiromic BioPharma’s Deltacel Receives FDA Fast Track DesignationNASDAQ:KRBPKiromic BioPharma Inc
09/08/202421:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRBPKiromic BioPharma Inc
09/08/202414:00Business WireKiromic BioPharma Provides Update on Part 1 of the Deltacel-01 TrialNASDAQ:KRBPKiromic BioPharma Inc
01/08/202414:00Business WireKiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01NASDAQ:KRBPKiromic BioPharma Inc
18/07/202414:00Business WireKiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion PhaseNASDAQ:KRBPKiromic BioPharma Inc
28/06/202422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRBPKiromic BioPharma Inc
20/06/202414:00Business WireKiromic BioPharma Provides Updates on its Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
06/06/202414:00Business WireKiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
29/05/202414:00Business WireKiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
22/05/202423:03Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRBPKiromic BioPharma Inc
20/05/202423:00Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:KRBPKiromic BioPharma Inc
20/05/202414:00Business WireKiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial SiteNASDAQ:KRBPKiromic BioPharma Inc
20/05/202412:29Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KRBPKiromic BioPharma Inc
17/05/202422:43Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KRBPKiromic BioPharma Inc
24/04/202414:08Business WireKiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three PatientsNASDAQ:KRBPKiromic BioPharma Inc
10/04/202422:30Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:KRBPKiromic BioPharma Inc
02/04/202414:18Business WireKiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
21/03/202422:21Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:KRBPKiromic BioPharma Inc
19/03/202413:08Business WireEarly Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
01/03/202414:08Business WireKiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialNASDAQ:KRBPKiromic BioPharma Inc
29/02/202400:30Business WireKiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7thNASDAQ:KRBPKiromic BioPharma Inc
14/02/202414:08Business WireResults from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two MonthsNASDAQ:KRBPKiromic BioPharma Inc
29/01/202413:47Business WireKiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung CancerNASDAQ:KRBPKiromic BioPharma Inc
05/01/202414:08Business WireKiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
14/12/202314:17Business Wire Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung CancerNASDAQ:KRBPKiromic BioPharma Inc
13/09/202322:35Business WireKiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14NASDAQ:KRBPKiromic BioPharma Inc
15/08/202322:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KRBPKiromic BioPharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KRBP

La tua Cronologia

LSE
PH55
Diageo Fin. 44
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network